Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Plasmapheresis (PLEX) and intravenous immunoglobulin (IVIg) are commonly used to treat autoimmune neuromuscular disorders, including myasthenia gravis, acute inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, and other autoimmune neurological disorders. The side effect profiles of these therapies vary, and concern has been raised regarding the safety of PLEX in the elderly population. In this study, we have examined the pattern of PLEX and IVIg use for autoimmune neurological disorders at a single facility and in a national database, focusing on the complications in elderly patients.
Methods: We performed a retrospective chart review of adult patients at our institution receiving PLEX or IVIg for any autoimmune neuromuscular or neuro-immunological disease. Next, we analyzed the National Inpatient Sample database to confirm the trend in IVIg and PLEX use from 2012 to 2018 for a set of neuromuscular and neuro-immunological primary diagnoses.
Results: IVIg was overall favored over PLEX. The adverse effects were similar among elderly patients (age ≥65 years) compared with younger patients (<65 years) in our institution, even after adequate matching of patients based on age, sex, and medical history. We examined the National Inpatient Sample dataset and noted increasingly higher frequency of IVIg use, consistent with the findings from our institution or facility.
Conclusions: Both PLEX and IVIg are safe therapeutic choices in adult patients with autoimmune neuromuscular disorders and other neuro-immunological diseases and can be safely administered in the appropriate clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CND.0000000000000439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The changing landscape of primary autoimmune neuropathies.
Nat Rev Neurol
September 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau (IR SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.
Autoimmune neuropathies, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are rare, disabling disorders. Diagnosis, follow-up and treatment of autoimmune neuropathies rely almost exclusively on clinical parameters, and the available therapies, such as intravenous immunoglobulins and corticosteroids, date from >30 years ago. The lack of therapeutic progress in autoimmune neuropathies has resulted from a combination of limited understanding of their pathophysiology, disease heterogeneity and challenges in trial design.
View Article and Find Full Text PDFCongenital Myasthenic Syndrome in Pregnancy: A Case Report and Literature Review on Peripartum Management Strategy.
Cureus
August 2025
Department of Anaesthesiology and Critical Care, Faculty of Medicine, University of Peradeniya, Kandy, LKA.
Congenital myasthenic syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by defects in neuromuscular transmission. Unlike autoimmune myasthenia gravis, CMS typically presents in childhood with variable severity and symptoms, and does not involve autoantibodies. This report presents the management of a primigravida diagnosed with CMS who was generally stable on pyridostigmine therapy but experienced a severe exacerbation during pregnancy.
View Article and Find Full Text PDFItem selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project.
Semin Arthritis Rheum
August 2025
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden. Electronic address:
Objective: A revision of the 2017 EULAR-ACR myositis classification criteria, namely EULAR-ACR funded Myositis Revision of Classification (MyoROC) project, is currently underway involving a large international group of experts. In the first phase of this project, we identified additional items to be tested in the criteria.
Methods: We distributed an electronic survey to International Myositis Assessment and Clinical Studies (IMACS) members to identify new items.
CFHR2 Supplementation Mitigates Pathologies of Neuromyelitis Optica by Regulating Complement Activation.
Mol Ther
September 2025
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. Electronic address:
Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease primarily affecting the optic nerves and spinal cord. While the pathogenesis of NMO involves Aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage, the specific roles of the complement pathway remain to be fully elucidated. In this study, we found that complement factor H-related protein 2 (CFHR2), a regulator that inhibits the complement C3 alternative pathway, was significantly decreased in the serum of NMO patients and was negatively correlated with the Expanded Disability Status Scale (EDSS) score.
View Article and Find Full Text PDFNext-generation approaches in autoimmune encephalitis diagnosis: A multi-omics perspective.
J Neuroimmunol
August 2025
Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China; Clinical Research Center for Epileptic Disease of Hunan Province, C
Autoimmune encephalitis (AE) is a group of autoantibody-mediated inflammatory disorders of the central nervous system (CNS) that often present with cognitive deficits, behavioral abnormalities, and seizures. The subtypical variability of AE calls for individualized treatments based on specific antibodies and clinical manifestations. Early and accurate diagnosis and standardized treatment are essential to improve prognosis and promote neurological recovery.
View Article and Find Full Text PDF